These findings, therefore, indicated that EPS301-adjuvanted intranasal vaccination could elicit strong and long-term mucosal IgA and systemic IgG, as well as promote sustained resistance to P. aeruginosa-induced pneumonia. Here, CD79A is linked to susceptibility to pneumonia measurement.